biostudies-literatureUnknown18(6)Loi SPfizer Inc<h4>Aim</h4>Palbociclib was approved in the United States in 2015 to treat estrogen receptor-positive/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC). This study evaluated outcomes and safety in patients treated with palbociclib in Australia and India with hormone receptor-positive (HR+)/HER2- ABC before palbociclib became commercially available.<h4>Methods</h4>Postmenopausal women (≥18 years) with HR+/HER2- ABC who were appropriate candidates for letrozole therapy received palbociclib 125 mg once daily for 21 days followed by 7 days off, and letrozole 2.5 mg once daily (continuous). Safety, tumor response, and patient-reported outcomes (Australian cohort) were evaluated.<h4>Results</h4>In total, 252 patients received palbociclib plus letrozole (AustrAsia-Pacific journal of clinical oncology560-569https://www.ebi.ac.uk/biostudies/studies/S-EPMC9787838biostudies-literaturePalbociclib plus letrozole as treatment for postmenopausal women with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer for whom letrozole therapy is deemed appropriate: An expanded access study in Australia and India.PMC9787838McCarthy NLu DRWhite MGore VRedfern ABoyle FDoval DCAlam MKim SKarapetis CSKhasraw MOakman CLoi SBinko JfalsePalbociclib plus letrozole as treatment for postmenopausal women with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer for whom letrozole therapy is deemed appropriate: An expanded access study in Australia and India.<h4>Aim</h4>Palbociclib was approved in the United States in 2015 to treat estrogen receptor-positive/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC). This study evaluated outcomes and safety in patients treated with palbociclib in Australia and India with hormone receptor-positive (HR+)/HER2- ABC before palbociclib became commercially available.<h4>Methods</h4>Postmenopausal women (≥18 years) with HR+/HER2- ABC who were appropriate candidates for letrozole therapy received palbociclib 125 mg once daily for 21 days followed by 7 days off, and letrozole 2.5 mg once daily (continuous). Safety, tumor response, and patient-reported outcomes (Australian cohort) were evaluated.<h4>Results</h4>In total, 252 patients received palbociclib plus letrozole (Austr2022-01-01T00:00:00Z2022 Dec2026-05-31T02:16:59.069Z2025-04-04T21:00:30.01ZS-EPMC97878383490823510.1111/ajco.13653